High-dose chemotherapy in adult acute myeloid leukemia: Rationale and results

Leukemia Research

Volumn 20, Issue 7, 1996, Pages 535-549

  Stasi, Roberto ^a,b   Venditti, Adriano ^a   Del Poeta, Giovanni ^a   Aronica, Germano ^a   Abruzzese, Elisabetta ^a   Pisani, Francesco ^a   Cecconi, Manrico ^a   Masi, Mario ^a   Amadori, Sergio ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b NONE   (Italy)

Author keywords

Acute myeloid leukemia; Adult; Cytosine arabinoside; Daunorubicin; High dose chemotherapy; Mitoxantrone

Indexed keywords

AMSACRINE; ANTILEUKEMIC AGENT; ASPARAGINASE; CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; CYTOTOXIC AGENT; DAUNORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IDARUBICIN; INTERLEUKIN 3; MERCAPTOPURINE; METHOTREXATE; MITOXANTRONE; PREDNISONE; TIOGUANINE; VINCRISTINE; ZORUBICIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ALLOGENIC BONE MARROW TRANSPLANTATION; AUTOLOGOUS BONE MARROW TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CHILD; CLINICAL TRIAL; CYTOGENETICS; DOSE RESPONSE; FEMALE; HUMAN; KARYOTYPE; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; PRESCHOOL CHILD; PRIORITY JOURNAL; REMISSION; REVIEW; SCHOOL CHILD;

EID: 0030198898     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/0145-2126(96)00016-1     Document Type: Review

References (70)

1. 1. Stone R. M. & Mayer R. J. (1993) Treatment of the newly diagnosed adult with de novo acute myeloid leukemia. Hematol. Oncol. Clin. North Am. 7, 47.
2. 2. Mandelli F., Avvisati G. & Petti M. C. (1993) Therapy of acute myeloid leukemia: where from now? In Hematology Trends '93 (Lechner K. & Gadner H., Eds), p. 200. Schattauer, Stuttgart.
3. 3. Skipper H. E. (1967) Criteria associated with destruction of leukemia and solid tumor cells in animals. Cancer Res. 27, 2636.
4. 4. Goldie J. H. & Goldman A. J. (1979) A mathematical model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat. Rep. 63, 1727.
5. 5. Coldman A. J. & Goldie J. H. (1987) Impact of dose-intense chemotherapy on the development of permanent drug resistance. Semin. Oncol. 14, (suppl. 4), 29.
6. 6. Butturini A. & Gale R. P. (1989) How can we cure leukemia? Br. J. Haematol. 72, 479.
7. 7. Preisler H., Davis K. B., Kirshner J., et al. (1987) Comparison of three remission induction regimens and two postinduction strategies for the treatment of acute nonlymphocytic leukemia: A Cancer and Leukemia Group B Study. Blood 69, 1441.
8. 8. Bishop J. F., Lowenthal R. M., Joshua D., et al. (1990) Etoposide in acute nonlymphocytic leukemia. Blood 75, 27.
9. 9. Skipper H. E., Schabel F. M. Jr., Wilcox W. S., et al. (1967) Experimental evaluation of potential anticancer agents XXI. Scheduling of arabinosyl-cytosine to take advantage of its S-phase specificity against leukemic cells. Cancer Chemother. Rep. 51, 125.
10. 10. Dillman R. O., Davis R. B., Green M. R., et al. (1991) A comparative study of two different doses of cytarabine for acute myeloid leukemia: A phase III trial of Cancer and Leukemia Group B. Blood 78, 2520.
11. 11. Rai K. R., Holland J. R., Glidewell O. J., et al. (1981) Treatment of acute myelocytic leukemia: a study by the Cancer and Leukemia Group B. Blood 58, 1203.
12. 12. Rees J. K. H., Gray R. G. & Hayhoe F. G. J. (1987) Treatment of acute myeloid leukemia (AML) with 1+5 DAT or 3 + 10 DAT induction and intensive consolidation. Early results in 9th MRC AML trial. 4th International Symposium on the Therapy of Acute Leukemias, Rome, 7-12 February 1987. Abstract Book: 189 (abstract).
13. 13. Rudnick S. A., Cadman E. C., Capizzi R. L., et al. (1979) High-dose cytosine arabinoside (HDARAC) in refractory acute leukemia. Cancer 44, 1189.
14. 14. Herzig R. H., Wolff S. N., Lazarus H. M., et al. (1983) High-dose cytosine arabinoside therapy for refractory leukemia. Blood 62, 361.
15. 15. Capizzi R. L., Poole M., Cooper M. R., et al. (1983) Treatment of poor-risk acute leukemia with sequential high-dose ara-C and asparaginase. Blood 63, 694.
16. 16. Wells R. J., Feusner J., Devney R., et al. (1985) Sequential high-dose cytosine arabinoside-asparaginase treatment in advanced childhood leukemia. J. Clin. Oncol. 3, 998.
17. 17. Amadori S., Papa G., Avvisati G., et al. (1984) Sequential combination of systemic high-dose ara-C and asparaginase for the treatment of central nervous system leukemia and lymphoma. J. Clin. Oncol. 2, 98.
18. 18. Morra E., Lazzarino M., Brusamolino E., et al. (1993) The role of systemic high-dose cytarabine in the treatment of central nervous system leukemia. Clinical results in 46 patients. Cancer 72, 439.
19. 19. Rubin E. H., Andersen J. W., Berg D. T., et al. (1992) Risk factors for high-dose cytarabine, neurotoxicity: an analysis of a Cancer and Leukemia Group B trial in patients with acute myeloid leukemia. J. Clin. Oncol. 10, 948.
20. 20. Plunkett W., Lillemark O. J., Adams T. M., et al. (1987) Saturation of 1-ß-D-arabinosylcytosine 5′-triphosphate accumulation in leukemia cells during high-dose 1-ß-D-arabinosylcytosine therapy. Cancer Res. 47, 3005.
21. 21. Estey E. H., Plunkett W., Kantarjian H., et al. (1993) Treatment of relapsed or refractory AML with intermediate-dose arabynosylcytosine: confirmation of the importance of ara-C triphosphate formation in mediating response to ara-C.. Leuk. Lymph. 15, (Suppl. 10), 115.
22. 22. Hiddemann W., Schleyer E., Uhrmeister C., et al. (1990) High-dose versus intermediate-dose cytosine arabinoside in combination with mitoxantrone for the treatment of relapsed and refractory acute myeloid leukemia. Preliminary clinical and pharmacological data of a randomized comparison. Cancer Treat. Rev. 17, 279.
23. 23. Curtis J. E., Messner H. A., Minden M. D., et al. (1987) High-dose cytosine arabinoside in the treatment of acute myelogenous leukemia: contributions to outcome of clinical and laboratory attributes. J. Clin. Oncol. 5, 532.
24. 24. Phillips G. L., Reece D. E., Shepherd J. D., et al. (1991) High-dose cytarabine and daunorubicin induction and postremission chemotherapy for the treatment of acute myelogenous leukemia in the elderly. Blood 77, 1429.
25. 25. Keating M. J., Cork A., Broach Y., et al. (1987) Towards a clinically relevant cytogenetic classification of acute myelogenous leukemia. Leukemia Res. 11, 119.
26. 26. Mitus J., Miller K. B., Schenkein D. P., et al. (1995) Improved survival for patients with acute myelogenous leukemia. J. Clin. Oncol. 13, 560.
27. 27. Vaughan W. P., Karp J. E. & Burke P. J. (1980) Long chemotherapy-free remissions after single-cycle timed-sequential chemotherapy for acute myelocytic leukemia. Cancer 45, 859.
28. 28. Karp J. E., Donehower R. C., Dole G., et al. (1987) Correlation of drug-perturbed marrow cell growth kinetics and intracellular of 1-ß-D-furanosylcytosine metabolism with clinical response in adult acute myelogenous leukemia. Blood 69, 1134.
29. 29. Martens A. C. M., Van Bekkum D. W. & Hagenbeek A. (1990) The BN acute myelocytic leukemia (BNML): a rat model for studying human acute myelocytic leukemia. Leukemia 4, 244.
30. 30. Heinemann V., Estey E., Keating M. J., et al. (1989) Patient-specific dose rate for continuous infusion high-dose cytarabine in relapsed acute myelogenous leukemia. J. Clin. Oncol. 7, 622.
31. 31. Estey E., Keating M. J. & Plunkett W. (1987) Continuous infusion high-dose cytosine arabinoside as induction and intensification therapy in adults under age 50 with newly-diagnosed acute myelogenous leukemia. Semin. Oncol. 14, (Suppl. 1), 58.
32. 32. Estey E. H., Kantarjian H. & Keating M. (1993) Idarubicin plus continuous infusion high-dose cytarabine as treatment for patients with acute myelogenous leukemia or myelodysplastic syndrome. Semin. Oncol. 20, (Suppl. 8), 1.
33. 33. Ghaddar H. M., Plunkett W., Kantarjian H. M., et al. (1994) Long-term results following treatment of newly-diagnosed acute myelogenous leukemia with continuous infusion high-dose cytosine arabinoside. Leukemia 8, 1269.
34. 34. Weick J., Kopecky J., Appelbaum F., et al. (1992) A randomized investigation of high-dose versus standard dose cytosine with daunorubicin in patients with acute myelogenous leukemia (Abstract). Proc. Am. Soc. Clin. Oncol. 11, 261.
35. 35. Schiller G., Gajewski J., Nimer S., et al. (1992) A randomized study of intermediate versus conventional-dose cytarabine as intensive induction for acute myelogenous leukaemia. Br. J. Haematol. 81, 170.
36. 36. Büchner T., Hiddemann W., Schaefer W., et al. (1992) Combined effect of very early intensification and prolonged post-remission chemotherapy in patients with AML. Leukemia 6, (Suppl. 4), 68.
37. 37. Bishop J. F., Matthews J. P., Young G. A., et al. (1994) High dose cytosine arabinoside in induction prolongs remission in acute myeloid leukemia (AML): updated results of a randomized phase III trial (Abstract). Blood 84, (Suppl. 1), 232a.
38. 38. Appelbaum F. R., Dahlberg S., Thomas E. D., et al. (1984) Bone marrow transplantation or chemotherapy after remission induction for adults with acute nonlymphoblastic leukemia. A prospective comparison. Ann. Int. Med. 101, 581.
39. 39. Yates J. W., Wallace H. J., Ellison R. R., et al. (1973) Cytosine arabinoside (NSC-63878) and daunorubicin (NSC-83142) therapy in acute nonlymphocytic leukemia. Cancer Chemother. Rep. 57, 485.
40. 40. Head D. R., Kopecky K. J., Weick J., et al. (1995) Effect of aggressive daunomycin therapy on survival in acute promyclocytic leukemia. Blood 86, 1717.
41. 41. Feldman E. J., Alberts D. S., Arlin Z., et al. (1993) Phase I clinical and pharmacokinetic evaluation of high-dose mitoxantrone in combination with cytarabine in patients with acute leukemia. J. Clin. Oncol. 10, 2002.
42. 42. Bloomfield C. D. (1985) Postremission therapy in acute myeloid leukemia. J. Clin. Oncol. 3, 1570.
43. 43. Tallman M. S., Appelbaum F. R., Amos D., et al. (1987) Evaluation of intensive postremission chemotherapy for adults with acute nonlymphocytic leukemia using high-dose cytosine arabinoside with L-asparaginase and amsacrine with etoposide. J. Clin. Oncol. 5, 918.
44. 44. Preisler H., Raza A., Early A., et al. (1987) Intensive remission consolidation therapy in the treatment of acute nonlymphocytic leukemia. J. Clin. Oncol. 5, 722.
45. 45. Tricot G., Boogaerts M. A., Vlietinck R., et al. (1987) The role of intensive remission induction and consolidation therapy in patients with acute myeloid leukaemia. Br. J. Haematol. 66, 37.
46. 46. Wolff S. N., Herzig R. H., Fay J. W., et al. (1989) High dose cytarabine and daunorubicin as consolidation therapy for acute myeloid leukemia in first remission: long-term follow-up and results. J. Clin. Oncol. 7, 1260.
47. 47. Kurrle E., Ehninger G., Freund M., et al. (1989) A multicentre study on intensive induction and consolidation therapy in acute myelogenous leukemia. Blut 56, 233.
48. 48. Champlin R., Gajewski J., Nimer S., et al. (1990) Postremission chemotherapy for adults with acute myelogenous leukemia: improved survival with high-dose cytarabine and daunorubicin consolidation treatment. J. Clin. Oncol. 8, 1199.
49. 49. Schiller G., Gajewski J., Territo M., et al. (1992) Long-term outcome of high-dose cytarabine-based consolidation chemotherapy for adults with acute myelogenous leukemia. Blood 82, 2977.
50. 50. Harousseau J. L., Milpied N., Briere J., et al. (1991) Double intensive consolidation chemotherapy in adult acute myeloid leukemia. J. Clin. Oncol. 9, 1432.
51. 51. Cassileth P. A., Lynch E., Mines J. D., et al. (1992) Varying intensity of postremission therapy in acute myeloid leukemia. Blood 79, 1924.
52. 52. Mayer R. J., Davis R. B., Schiffer C. A., et al. (1994) Intensive remission chemotherapy in adults with acute myeloid leukemia. N. Engl. J. Med. 331, 896.
53. 53. Bloomfield C. D., Lawrence D., Arthur D. C., et al. (1994) Curative impact of intensification with high-dose cytarabine in acute myeloid leukemia varies by cytogenetic group (Abstract). Blood 84, 111a.
54. 54. Zittoun R., Mandelli F., Willemze R., et al. (1995) Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. N. Engl. J. Med. 332, 217.
55. 55. Rowe J. M., Andersen J. W., Mazza J. J., et al. (1995) A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (>55 to 70 years of age) with acute myelogenous leukemia: a study of the Eastern Cooperative Oncology Group (E 1490). Blood 86, 457.
56. 56. Stone R. M., Berg D. T., George S. L., et al. (1995) Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. N. Engl. J. Med. 332, 1671.
57. 57. Dombret H., Chastang C., Fenaux P., et al. (1995) A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia. N. Engl. J. Med. 332, 1678.
58. 58. Godwin J. E., Kopecky K. J., Head D. R., Hynes H. E., Balcerzak S. P. & Appelbaum F. R. (1995) A double blind placebo controlled trial of G-CSF in elderly patients with previously untreated acute myeloid leukemia. A Southwest Oncology Group Study (Abstract #1723). Blood 86, 434a.
59. 59. Heil G., Hoelzer D., Sanz M. A., et al. (1995) Results of a randomised, double-blind placebo controlled phase III study of filgrastim in remission induction and early consolidation therapy for adults with de novo acute myeloid leukaemia (Abstract #1053). Blood 86, 267a.
60. 60. Stasi R., Del Poeta G., Masi M., et al. (1993) Incidence of chromosome abnormalities and clinical significance of karyotype in de novo acute myeloid leukemia. Cancer Genet. Cytogenet. 67, 28.
61. 61. Miyauchi J., Kelleher C. A., Yang Y. C., et al. (1987) The effects of three recombinant growth factors, IL-3, GM-CSF, and G-CSF, on the blast cells of acute myeloblastic leukemia maintained in short-term suspension culture. Blood 70, 657.
62. 62. Vellenga E., Young D. C., Wagner K., Wiper D., Ostapovicz D. & Griffin J. D. (1987) The effects of GM-CSF and G-CSF in promoting growth of clonogenic cells in acute myeloblastic leukemia. Blood 69, 1771.
63. 63. Tafuri A. & Andreeff M. (1990) Kinetic rationale for cytokine-induced recruitment of myeloblastic leukemia followed by cycle-specific chemotherapy in vitro. Leukemia 4, 826.
64. 64. Powell B. L., Cruz J. M. Lyverly E. S., et al. (1993) Sequential high-dose Ara-C in untreated AML. Efficacy of a single daily dose of high-dose Ara-C. Blood 82, (Suppl. 1), 129a.
65. 65. Mehta J., Powles R. Treleaven J., et al. (1994) High-dose Ara-C and VP-16 with or without idarubicin for induction of remission in untreated primary acute myeloid leukemia. Blood 84, (Suppl. 1), 145.
66. 66. Brown R. A., Wolff S., Fay J., et al. (1994) High-dose cytosine arabinoside (HIDAC)/daunorubicin (DNR) induction followed by high-dose etoposide/cyclophosphamide consolidation for patients with AML (Abstract). Blood 84, (Suppl. 1), 146a.
67. 67. Ohno R., Tomonaga M., Kobayashi T., et al. (1990) Effect of granulocyte colony-stimulating factor after intensive induction therapy in relapsed or refractory acute leukemia. N. Engl. J. Med. 323, 871.
68. 68. Estey E. H., Dixon D., Kantarjan H. M., et al. (1990) Treatment of poor prognosis, newly diagnosed acute myeloid leukemia with Ara-C and recombinant human granulocyte-macrophage colony-stimulating factor. Blood 75, 1766.
69. 69. Büchner T., Hiddemann W., Koenigsmann M., et al. (1991) Recombinant human granulocyte-macrophage colony-stimulating factor after chemotherapy in patients with acute myeloid leukemia at higher age or after relapse. Blood 78, 1190.
70. 70. Baer M. R., Christiansen N. P., Frankel S. R., et al. (1993) High-dose cytarabine, idarubicin, and granulocyte colony-stimulating factor remission induction therapy for previously untreated de nova and secondary adult acute myeloid leukemia. Semin Oncol 20, (Suppl. 8), 6.